Alyssa A. Pullano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alyssa A. Pullano has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Lyuba Bolkhovitinov
HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
3 shared publications- Mark Connors
National Institute of Allergy and Infectious Diseases
3 shared publications - Andrew B. Ward
Department of Integrative Structural and Computational Biology, The Scripps Research Institute
2 shared publications Andy Patamawenu
HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
2 shared publications- Andy S. Tran
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, USA
2 shared publications Benjamin Leach
HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
2 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response
HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induces autologous neutralizing antibodies. However, durable neutralizing antibodies are induced only when multiple features of a replicating virus infection are combined, with the largest impact from dose and escalating dose. In summary, we show here immunogenicity of HIV-1 Env could be improved by reproducing features of virus infection.
- 3 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessAntigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response
HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induces autologous neutralizing antibodies. However, durable neutralizing antibodies are induced only when multiple features of a replicating virus infection are combined, with the largest impact from dose and escalating dose. In summary, we show here immunogenicity of HIV-1 Env could be improved by reproducing features of virus infection.
- Open Access
- 23 December 2024
- Published by Springer Nature in Research Square
Antigen Dose and Persistence Contribute to Induction of a Durable HIV-1-Specific Neutralizing Antibody Response
The immunogenicity of HIV-1 Env glycoprotein (Env) is limited in part by its structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies but often require many immunizations and the response is short-lived. To understand the parameters that confer a durable neutralizing antibody response, we used a Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and varied the conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin (HA), or SARS-CoV2 Spike (S)-bearing VLPs were used as controls. HA or S bearing VLPs rapidly induced neutralizing antibodies, whereas they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induced autologous neutralizing antibodies, suggesting glycan shielding or the naïve B cell repertoire were not barriers. We then tested the parameters that might approximate a replicating virus infection. Only when multiple features of a virus infection were combined did we observe durable neutralizing antibodies, with the largest impact attributable to dose and escalating dose. Our results suggest that numerous features of a replicating virus infection, including stabilization, spike density, TLR stimulation, total dose, and persistence of antigen, can be combined to improve the immunogenicity of HIV-1 Env.
- 23 December 2024
- Published by Springer Nature in Research Square
Open AccessAntigen Dose and Persistence Contribute to Induction of a Durable HIV-1-Specific Neutralizing Antibody Response
The immunogenicity of HIV-1 Env glycoprotein (Env) is limited in part by its structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies but often require many immunizations and the response is short-lived. To understand the parameters that confer a durable neutralizing antibody response, we used a Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and varied the conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin (HA), or SARS-CoV2 Spike (S)-bearing VLPs were used as controls. HA or S bearing VLPs rapidly induced neutralizing antibodies, whereas they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induced autologous neutralizing antibodies, suggesting glycan shielding or the naïve B cell repertoire were not barriers. We then tested the parameters that might approximate a replicating virus infection. Only when multiple features of a virus infection were combined did we observe durable neutralizing antibodies, with the largest impact attributable to dose and escalating dose. Our results suggest that numerous features of a replicating virus infection, including stabilization, spike density, TLR stimulation, total dose, and persistence of antigen, can be combined to improve the immunogenicity of HIV-1 Env.
- 12 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (34)
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
Ad4-H5 vaccine induces prolonged increases in H5-specific B cell frequency, antibody affinity, and somatic hypermutation.
- 12 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (34)
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
Ad4-H5 vaccine induces prolonged increases in H5-specific B cell frequency, antibody affinity, and somatic hypermutation.